Boehringer Ingelheim continues search for Alzheimer’s treatment despite trial set-back

Ciaran Arthurs's picture
20 February 2018 – Boehringer Ingelheim have shifted their attention to a new compound to treat Alzheimer’s disease, after topline results of two Phase II trials of BI 409306 showed that it did not have efficacy when tested for Alzheimer’s disease. There is hope for future success...
Last modified: 
Tuesday, 20 February, 2018 - 15:33